Zobrazeno 1 - 10
of 1 657
pro vyhledávání: '"glucose-dependent insulinotropic polypeptide"'
Autor:
David Vogrinc, Sara Redenšek Trampuž, Tanja Blagus, Maja Trošt, Milica Gregorič Kramberger, Andreja Emeršič, Saša Čučnik, Katja Goričar, Vita Dolžan
Publikováno v:
Heliyon, Vol 10, Iss 20, Pp e39157- (2024)
Background: Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases. Their treatment options are rather limited, and no neuroprotective or disease-modifying treatments are available. Anti-diabetic drugs, s
Externí odkaz:
https://doaj.org/article/281d39e356af4525ac6543a3111774c3
Autor:
Tayla A. Rees, Benjamin J. Buttle, Zoe Tasma, Sung-Hyun Yang, Paul W. R. Harris, Christopher S. Walker
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Type 2 diabetes (T2D) and obesity are prevalent metabolic disorders affecting millions of individuals worldwide. A new effective therapeutic drug called tirzepatide for the treatment of obesity and T2D is a dual agonist of the GIP receptor and GLP-1
Externí odkaz:
https://doaj.org/article/0907ffccbaea49f58081214071b5e048
Autor:
Jang Won Son, Soo Lim
Publikováno v:
Endocrinology and Metabolism, Vol 39, Iss 2, Pp 206-221 (2024)
Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focu
Externí odkaz:
https://doaj.org/article/76511dc6bdf24a9cb8f6551fad04c232
Autor:
Olorunsola Israel Adeyomoye, Juliana Bunmi Adetunji, Olugbemi Temitope Olaniyan, Charles Oluwaseun Adetunji, Doris Yinka Oluwafemi
Publikováno v:
Phytomedicine Plus, Vol 4, Iss 3, Pp 100594- (2024)
Background: Diabetes mellitus remains a critical global health issue, driving the need for continual exploration of new therapeutic strategies. Ficus exasperata Vahl, renowned for its extensive ethnomedicinal use, holds promise as a potential remedy
Externí odkaz:
https://doaj.org/article/ed1fb6ac840e48d4bc7f33465cdff175
Publikováno v:
Obesity Science & Practice, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract Background Anti‐obesity medications (AOMs) have historically had limited weight‐loss efficacy. However, newer glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)–based therapies seem to be more effective, including dual agonists
Externí odkaz:
https://doaj.org/article/14e2bc0e80c5425c99e6b0c9950d24c0
Autor:
Akihiro Hamasaki, Norio Harada, Atsushi Muraoka, Shunsuke Yamane, Erina Joo, Kazuyo Suzuki, Nobuya Inagaki
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
IntroductionIncretin-based drugs are extensively utilized in the treatment of type 2 diabetes (T2D), with remarkable clinical efficacy. These drugs were developed based on findings that the incretin effect is reduced in T2D. The incretin effect in Ea
Externí odkaz:
https://doaj.org/article/8161b599d06c43c2847ed02fe5a9a957
Autor:
Niya Narayanan, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Haritha Sagili, Bobby Zachariah, Dukhabandhu Naik, Ayan Roy, Chandhana Merugu
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 28, Iss 1, Pp 71-79 (2024)
Introduction: The aim of this study was to compare insulin sensitivity, islet cell function, and incretin axes in pregnant subjects with GDM and normal healthy controls. Methods: Pregnant women at 24 to 28 weeks of gestation were subjected to a 75 g
Externí odkaz:
https://doaj.org/article/3b55320154a44a1e831cef8f5eb2d2c1
Publikováno v:
Farmacja Polska, Vol 79, Iss 5, Pp 289-296 (2023)
Type 2 diabetes and obesity are civilization diseases with an ever-increasing number of cases. Obesity, which is an excessive accumulation of visceral body fat, is considered to be one of the main causes of type 2 diabetes. It promotes the accumulati
Externí odkaz:
https://doaj.org/article/b2f7295ef2ac40958899c4522535bb8a
Autor:
Antonio Ceriello, Helena W. Rodbard, Tadej Battelino, Frank Brosius, Francesco Cosentino, Jennifer Green, Linong Ji, Monika Kellerer, Susan Koob, Mikhail Kosiborod, Nebojsa Lalic, Nikolaus Marx, T. Prashant Nedungadi, Christopher G. Parkin, Lars Rydén, Wayne Huey-Herng Sheu, Eberhard Standl, Per Olav Vandvik, Oliver Schnell, for the Taskforce of the Guideline Workshop
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-5 (2023)
Abstract In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypepti
Externí odkaz:
https://doaj.org/article/27d5cfd5c6c14083a4d8c6448166a500
Publikováno v:
Biomolecules, Vol 14, Iss 7, p 872 (2024)
Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity. More recent developments of unimolecular peptides targeti
Externí odkaz:
https://doaj.org/article/1a0708b3bbf74cff8e3c580921120bfc